[关键词]
[摘要]
随着糖尿病患病率的增加和人群寿命的延长，糖尿病视网膜病变(DR)已成为许多国家工作年龄人群视力丧失的主要原因。DR发病机制错综复杂，目前尚未完全阐明，且DR的治疗手段未有较大改善，主要为视网膜激光光凝治疗、抗血管内皮生长因子(VEGF)治疗和玻璃体切割手术治疗，目前的治疗方法不仅存在短板，而且给患者带来严重的经济负担。所以需要新的方法探索DR的发病机制，发掘新的治疗手段或改良目前的治疗，提高DR患者满意度。近年来随着蛋白质组学的兴起，通过蛋白质组学定性定量技术识别、量化所有可观察到的DR患者和DR大鼠的血液、视网膜、玻璃体液、房水和泪液中表达的蛋白和药物干预后差异表达蛋白，为进一步探索DR发病机制、诊断和治疗提供了新思路，在DR早发现早治疗提出了新见解。文章就近年来DR的蛋白质组学进行综述，为DR的诊断与治疗提供新思路。
[Key word]
[Abstract]
Diabetic retinopathy(DR)has emerged as the leading cause of vision loss among working-age people in many countries under the increasing prevalence of diabetes and the longevity of the population. The pathogenesis of DR is complicated and has not been fully elucidated at present, while the treatment methods of DR have not been greatly improved, mainly retinal laser photocoagulation, anti-vascular endothelial growth factor(VEGF)treatment and vitrectomy surgery. The current treatment methods not only have shortcomings, but also bring serious economic burden to patients. Therefore, new methods are needed to explore the pathogenesis of DR, discover new treatments or improve current treatments, and improve the satisfaction of DR patients. In recent years, the identification and quantification of proteins expressed in blood, retina, vitreous humor, aqueous humor, and tears of all observable DR patients and DR rats and differentially expressed proteins after drug intervention have provided new ideas for further exploring the pathogenesis, diagnosis and treatment of DR with the rise of proteomics, which put forward new insights into early detection and treatment.The proteomics of DR in recent years are reviewed, in order to provide new ideas for the diagnosis and treatment of DR.
[中图分类号]
[基金项目]
北京医卫健康公益基金会医学科学研究基金项目(No.YWJKJJHKYJJ-KHE2403)
